The effects of everolimus on tuberous sclerosis-associated lesions can be dramatic but may be impermanent
- 7 September 2014
- journal article
- case report
- Published by Springer Nature in Pediatric Nephrology
- Vol. 30 (1) , 173-177
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012Pediatric Neurology, 2013
- Everolimus long-term safety and efficacy in subependymal giant cell astrocytomaNeurology, 2013
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialThe Lancet, 2013
- mTOR Inhibitors in Tuberous Sclerosis ComplexCurrent Neuropharmacology, 2012
- The Role of Tuberous Sclerosis Complex 1 in Regulating Innate ImmunityThe Journal of Immunology, 2012
- mTOR: from growth signal integration to cancer, diabetes and ageingNature Reviews Molecular Cell Biology, 2010
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous SclerosisNew England Journal of Medicine, 2010
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Renal Angiomyolipoma: Relationships between Tumor Size, Aneurysm Formation, and RuptureRadiology, 2002
- Causes of Death in Patients With Tuberous SclerosisMayo Clinic Proceedings, 1991